Current Report Filing (8-k)
July 12 2022 - 9:16AM
Edgar (US Regulatory)
0001522602
false
0001522602
2022-07-11
2022-07-11
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant To Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report: July 11, 2022
(Date of earliest event reported)
COHBAR, INC.
(Exact name of registrant as specified in its
charter)
Delaware |
|
001-38326 |
|
26-1299952 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(I.R.S. Employer
Identification No.) |
1455 Adams Drive, Suite 2050
Menlo Park, CA 94025
(Address of principal executive offices and
zip code)
(650) 446-7888
(Registrant’s telephone number, including
area code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any
of the following provisions (see General Instruction A.2. below):
| ☐ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting
material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b)) |
| ☐ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange
on which registered |
|
|
CWBR |
|
Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐
COHBAR, INC.
FORM 8-K
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On July 11, 2022, the board of directors
(the “Board”) of CohBar, Inc. (the “Company”) appointed Stephanie Tozzo to serve as director of the Company,
effective immediately.
In connection with her appointment as a member
of the Board, Dr. Tozzo was granted stock options to purchase 200,000 shares of the Company’s common stock, at an exercise price
of $0.197 per share (the “Option”). The Option will vest and become exercisable in equal monthly installments over a period
of four years based on Dr. Tozzo’s continued service to the Company during the vesting period. Dr. Tozzo will also receive annual
cash compensation of $60,000 in consideration of her service as a director.
Dr. Tozzo has served as Senior Vice President
and Chief Scientific Officer of Avilar Therapeutics, Inc. since November 2021. Prior to joining Avilar Therapeutics, Dr. Tozzo served
at Cellarity, Inc. (a Flagship Pioneering company) as Senior Vice President, Drug Development and Head of R&D from January 2020 to
November 2021 and at Mitobridge Inc. (later acquired by Astellas) as Senior Vice President, Translational Sciences from 2014 to 2020. Dr.
Tozzo began her career as a research scientist at ErgoScience Corp. in 1995 and held leading positions at Merck & Co., F. Hoffman-La
Roche Ltd., Bristol-Myers Squibb, Millennium Pharmaceuticals and Chiron Corporation from 1997 to 2014. She has a B.Sci. in Biochemistry
and Immunology from University of Paris 7 and an M.Sci. in Molecular and Cellular Endocrinology from University of Paris XI. Dr. Tozzo
received her Ph.D. in Molecular and Cellular Endocrinology from the University of Paris XI and completed her post-doctoral training in
the Endocrine Division at Beth Israel Hospital/Harvard Medical School in Boston.
There are no arrangements or understandings between
Dr. Tozzo and any other persons pursuant to which Dr. Tozzo was selected as a member of the Board. There are also no family relationships
between Dr. Tozzo and any director or executive officer of the Company, nor does Dr. Tozzo have a direct or indirect material interest
in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
COHBAR, INC. |
|
(Registrant) |
|
|
|
July 12, 2022 |
By: |
/s/ Jeffrey F. Biunno |
(Date) |
|
Jeffrey F. Biunno |
|
|
Chief Financial Officer |
2
CohBar (NASDAQ:CWBR)
Historical Stock Chart
From Mar 2024 to Apr 2024
CohBar (NASDAQ:CWBR)
Historical Stock Chart
From Apr 2023 to Apr 2024